España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
AbbVie
ABBV
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$171.56
-2.14
-1.23%
At close: -
$171.60
0.04
0.02%
After Hours: Jan 17, 7:12 PM EDT
Get Report
Comment
The dividend Ex-Date was 5 days ago
Q4 2024 Earnings in 11 days from now on Fri Jan 31st, before the market open
AbbVie (ABBV) Forecast
News
Earnings
AbbVie (ABBV) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for AbbVie (NYSE:ABBV) Stock
AbbVie Stock (NYSE: ABBV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 17, 2025
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Anthony Noto
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Vandana Singh
'Ozempic Is In The Next Round Of Medicare Dru...
Benzinga Newsdesk
Wednesday, January 15, 2025
AbbVie Exec Says Co Can Commit Less Capital P...
Benzinga Newsdesk
Tuesday, January 14, 2025
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Monday, January 13, 2025
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Vandana Singh
AbCellera Expands AbbVie Collaboration To Inc...
Benzinga Newsdesk
Simcere Zaiming And AbbVie Partner To Develop...
Benzinga Newsdesk
Friday, January 10, 2025
AbbVie Unusual Options Activity For January 10
Benzinga Insights
Wednesday, January 08, 2025
Assessing AbbVie: Insights From 17 Financial Analysts
Benzinga Insights
8 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Truist Securities Maintains Buy on AbbVie, Lo...
Benzinga Newsdesk
Tuesday, January 07, 2025
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
Benzinga Insights
Monday, January 06, 2025
AbbVie Announced Q4 2024 Earnings To Include ...
Benzinga Newsdesk
Friday, January 03, 2025
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor
Wednesday, December 25, 2024
Looking Into AbbVie's Recent Short Interest
Benzinga Insights
Tuesday, December 24, 2024
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Benzinga Insights
Monday, December 23, 2024
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Erica Kollmann
Sunday, December 22, 2024
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Vandana Singh
Thursday, December 19, 2024
Kevin K Buckbee Executes Sell Order: Offloads $310K In AbbVie Stock
Benzinga Insights
AbbVie's Atogepant And OnabotulinumtoxinA Rec...
Benzinga Newsdesk
Tuesday, December 17, 2024
AbbVie shares are trading higher after Piper ...
Benzinga Newsdesk
Piper Sandler Maintains Overweight on AbbVie,...
Benzinga Newsdesk
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Avi Kapoor
Friday, December 13, 2024
AbbVie To Acquire Nimble Therapeutics For $20...
Benzinga Newsdesk
Tuesday, December 10, 2024
Analyst Scoreboard: 19 Ratings For AbbVie
Benzinga Insights
B of A Securities Reinstates Neutral on AbbVi...
Benzinga Newsdesk
Monday, December 09, 2024
CNBC Halftime Report Final Trades: AbbVie, Ve...
Benzinga Newsdesk
AbbVie And Genmab A/S Present Two Data Analys...
Benzinga Newsdesk
Check Out What Whales Are Doing With ABBV
Benzinga Insights
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
Vandana Singh
AbbVie Announces Topline Results For The Phas...
Benzinga Newsdesk
Reported Saturday, AbbVie Unveils Phase 1b/2 ...
Benzinga Newsdesk
Reported Sunday, AbbVie's Emotional Impact Re...
Benzinga Newsdesk
Wednesday, December 04, 2024
Check Out What Whales Are Doing With ABBV
Benzinga Insights
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Vandana Singh
Tuesday, December 03, 2024
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
Avi Kapoor
Friday, November 29, 2024
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Benzinga Insights
Tuesday, November 26, 2024
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Vandana Singh
(ABBV) - Analyzing AbbVie's Short Interest
Benzinga Insights
Monday, November 25, 2024
Market Whales and Their Recent Bets on ABBV Options
Benzinga Insights
Friday, November 22, 2024
AbbVie shares are trading higher after Leerin...
Benzinga Newsdesk
On CNBC, Jim Lebenthal Announced Bought More ...
Benzinga Newsdesk
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Avi Kapoor
Leerink Partners Upgrades AbbVie to Outperfor...
Benzinga Newsdesk
Wednesday, November 20, 2024
Unpacking the Latest Options Trading Trends in AbbVie
Benzinga Insights
Monday, November 18, 2024
AbbVie Secures European Commission Approval F...
Benzinga Newsdesk
Sunday, November 17, 2024
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
Lekha Gupta
Friday, November 15, 2024
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
Avi Kapoor
Wolfe Research Initiates Coverage On AbbVie w...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch